Fenbufen in patients with gastric intolerance.
Forty-one patients with inflammatory or degenerative arthritis and a history of gastric disturbance on other non-steroid anti-inflammatory drugs, or of peptic ulceration were treated with fenbufen 600-1200 mg dialy, and followed up for 3-17 months in an open study. Twelve patients withdrew because of lack of effect of the drug on the arthritic symptoms. Four patients withdrew because of non-gastrointestinal side effects. Three patients withdrew because of continuing dyspepsia. Twenty-two patients continued on fenbufen without dyspepsia or evidence of gastro-intestinal bleeding for 3-17 months (mean 8.3 months). These results suggest that fenbufen can be tolerated by patients with a history of gastro-intestinal disturbance on other NSAIDs, and that a larger controlled study would be warranted.
D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D010438:Peptic Ulcer Hemorrhage / Q000139:chemically induced / Q000188:drug therapy; D010654:Phenylbutyrates; D011422:Propionates / Q000008:administration & dosage* / Q000009:adverse effects; D013270:Stomach / Q000187:drug effects; D013276:Stomach Ulcer / Q000150:complications
D000893:Anti-Inflammatory Agents; D010654:Phenylbutyrates; D011422:Propionates; C010725:fenbufen